The latest market report published
by Credence Research, Inc. “Global Anti-Hypertensive Drugs Market–
Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 –
2023,” the global anti-hypertensive drugs market was valued at
USD 32,214.3 Mn in 2015, and is expected to reach USD 34,925.7 Mn by 2023,
expanding at a CAGR of 1.2% from 2016 to 2023.
Browse the full report report
at http://www.credenceresearch.com/report/anti-hypertensive-drugs-market
Market Insights
Hypertension is commonly observed
chronic condition, in which the blood pressure is elevated abnormally both
systolic and diastolic. This is major risk factor for causing cardiovascular,
renal or endocrine disorder. The normal blood pressure level is 120-140mm Hg
systolic and 60-90mm Hg diastolic any elevation above it is considered as
hypertension. The major reason for the rise in prevalence of hypertension is
lifestyle change, unhealthy food habits and demographic ageing.
Anti-hypertensive drugs are used to reduce the level of blood pressure,
different drug class of drugs with different mechanism of action exist in the
market. The antihypertensive market is growing with increased patient pool
especially geriatric population and extensive research and development for
novel pipeline drug. The global antihypertensive market show robust growth in
forecast period, but it face threat of genericization and increased competition
due to patent expiry.
Anti-Hypertensive are categorized by
drug class type as Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin
converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium
channel blockers, Renin inhibitors and Vasodilators. ACE inhibitor occupies the
largest market share in terms of value due to mechanism of action and is
preferred in geriatric population and diabetes patient as first line of
treatment as antihypertensive drug. Beta blockers follow next in line due to
preference of physician over diuretic, which are most commonly used.
Download Free Sample @ http://www.credenceresearch.com/sample-request/58287
Based on the drug class type, the
global Anti-hypertensive drugs market is segmented as follows:
Diuretics
ACE inhibitors
ARBs
Calcium Channel Blockers
Beta – Adrenergic blocker
Alpha – Adrenergic blocker
Central Sympatholyics
Renin inhibitors
Vasodilators
As of the current market scenario,
North America is the largest regional market for anti-hypertensive drugs
market, followed by the Europe and Asia Pacific. The major factors driving the
North America rise in prevalence of hypertension and other associated chronic
disease especially in geriatric population, novel drugs in pipeline and
upcoming use of combination therapies. Europe major market contributor are UK,
Germany, France, Italy and Spain due to factors such as increase in prevalence
of hypertension and unmet need for treatment of chronic disease, health care
program planning and expenditure. Asia-Pacific is the fastest growing market
due to rise population and incidence of chronic diseases due to alteration in
lifestyle changes; and health care infrastructure and government expenditure.
Thus developed market dominates the antihypertensive drugs market, with
developing economies booming at fast rate.
Market Competition Assessment:
Key players in the global
Anti-Hypertensive drugs market are
Novartis AG, Astra Zeneca, Pfizer
Inc., Acetelion Ltd, Sanofi S.A., Merck & Co., Boehringer Ingelheim, Lupin
Limited, Johnson & Johnson Ltd., Astra Zeneca Plc, Daiichi Sankyo
Company Limited and Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceutical,
Bayer AG etc.
Browse the full report report
at http://www.credenceresearch.com/report/anti-hypertensive-drugs-market
Key Market Movements:
Rising prevalence of hypertension
due to various factors such as growing population, change in unhealthy
lifestyle etc.
Extensive R&D for new treatment
regimen and new drug approval in pipeline
Evolving use of combination therapy
to lower the blood pressure and decrease in adverse effect
About Us:
Credence Research is a worldwide market research and counseling firm
that serves driving organizations, governments, non-legislative associations,
and not-for-benefits. We offer our customers some assistance with making
enduring enhancements to their execution and understand their most imperative
objectives. Over almost a century, we’ve manufactured a firm extraordinarily
prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
No comments:
Post a Comment